FDA Approves New Preventive Migraine Treatment

The FDA has approved Ajovy (fremanezumab-vfrm) injection, the first and only anti-CGRP treatment with quarterly (675 mg) and monthly (225 mg) dosing for the preventive treatment of migraine in adults.

The drug was evaluated in 2 Phase III, placebo-controlled trials of patients with disabling migraine and was evaluated as both a stand-alone and combination treatment. The trial results showed that patients given Ajovy saw reductions in the number of monthly migraine days during the 12-week study period.

The most common adverse events were injection site reactions.  AJOVY is contraindicated in individuals with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

—Michael Potts

Reference:

Teva announces US approval of Ajovy (fremanezumab-vfrm) injection, the first and only anti-cgrp treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults [press release]. September 14, 2018. https://www.tevapharm.com/news/.